Palatin Technologies, Inc. (PTN)
USD 0.75
(-9.64%)
USD 0.75
(-9.64%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -8.93 Million USD | -28.8% |
| 2023 | -6.93 Million USD | 75.89% |
| 2022 | -28.78 Million USD | 51.09% |
| 2021 | -58.85 Million USD | 27.86% |
| 2020 | -81.58 Million USD | -88.96% |
| 2019 | -43.17 Million USD | -36.13% |
| 2018 | -31.71 Million USD | -21.62% |
| 2017 | -26.07 Million USD | -322.63% |
| 2016 | 11.71 Million USD | 167.13% |
| 2015 | -17.45 Million USD | -43.22% |
| 2014 | -12.18 Million USD | 36.37% |
| 2013 | -19.14 Million USD | -405.88% |
| 2012 | -3.78 Million USD | 79.86% |
| 2011 | -18.79 Million USD | -249.86% |
| 2010 | -5.37 Million USD | -26.18% |
| 2009 | -4.25 Million USD | 52.89% |
| 2008 | -9.03 Million USD | 70.81% |
| 2007 | -30.95 Million USD | -10.49% |
| 2006 | -28.01 Million USD | -78.56% |
| 2005 | -15.69 Million USD | 12.26% |
| 2004 | -17.88 Million USD | -27.46% |
| 2003 | -14.03 Million USD | -76.61% |
| 2002 | -7.94 Million USD | 30.49% |
| 2001 | -11.42 Million USD | -254.97% |
| 2000 | -3.21 Million USD | -973.2% |
| 1999 | -300 Thousand USD | 91.67% |
| 1998 | -3.6 Million USD | 67.27% |
| 1997 | -11 Million USD | -211.09% |
| 1996 | -3.53 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -9.3 Million USD | -7.43% |
| 2024 Q2 | -8.66 Million USD | -88.73% |
| 2024 Q1 | -4.59 Million USD | 33.84% |
| 2024 Q4 | -9.1 Million USD | 3.98% |
| 2023 Q2 | -20.26 Million USD | -0.54% |
| 2023 Q3 | -18.83 Million USD | 7.06% |
| 2023 FY | -6.93 Million USD | 75.89% |
| 2023 Q1 | -20.15 Million USD | 29.98% |
| 2023 Q4 | -6.93 Million USD | 63.16% |
| 2022 Q1 | -52.25 Million USD | 11.2% |
| 2022 Q2 | -45.94 Million USD | 12.08% |
| 2022 Q3 | -36.45 Million USD | 20.66% |
| 2022 FY | -28.78 Million USD | 51.09% |
| 2022 Q4 | -28.78 Million USD | 21.03% |
| 2021 Q4 | -58.85 Million USD | 12.56% |
| 2021 Q1 | -85.39 Million USD | -4.67% |
| 2021 Q2 | -71.03 Million USD | 16.81% |
| 2021 FY | -58.85 Million USD | 27.86% |
| 2021 Q3 | -67.3 Million USD | 5.25% |
| 2020 Q4 | -81.58 Million USD | 8.27% |
| 2020 Q1 | -96.69 Million USD | -123.96% |
| 2020 FY | -81.58 Million USD | -88.96% |
| 2020 Q3 | -88.93 Million USD | 2.74% |
| 2020 Q2 | -91.44 Million USD | 5.43% |
| 2019 Q4 | -43.17 Million USD | -133.59% |
| 2019 Q3 | -18.48 Million USD | 17.25% |
| 2019 Q2 | -22.33 Million USD | 21.11% |
| 2019 Q1 | -28.31 Million USD | 10.73% |
| 2019 FY | -43.17 Million USD | -36.13% |
| 2018 FY | -31.71 Million USD | -21.62% |
| 2018 Q2 | -24.74 Million USD | 10.14% |
| 2018 Q1 | -27.53 Million USD | -5.6% |
| 2018 Q4 | -31.71 Million USD | -81.39% |
| 2018 Q3 | -17.48 Million USD | 29.34% |
| 2017 Q2 | 5.55 Million USD | -42.94% |
| 2017 FY | -26.07 Million USD | -322.63% |
| 2017 Q3 | -38.44 Million USD | -792.47% |
| 2017 Q1 | 9.72 Million USD | -16.95% |
| 2017 Q4 | -26.07 Million USD | 32.16% |
| 2016 Q4 | 11.71 Million USD | 659.54% |
| 2016 FY | 11.71 Million USD | 167.13% |
| 2016 Q1 | -27.93 Million USD | -60.09% |
| 2016 Q2 | -12.36 Million USD | 55.76% |
| 2016 Q3 | -2.09 Million USD | 83.06% |
| 2015 Q2 | -32.87 Million USD | -313.27% |
| 2015 FY | -17.45 Million USD | -43.22% |
| 2015 Q1 | -7.95 Million USD | 34.7% |
| 2015 Q3 | -26.89 Million USD | 18.19% |
| 2015 Q4 | -17.45 Million USD | 35.12% |
| 2014 Q3 | -16.71 Million USD | -0.25% |
| 2014 FY | -12.18 Million USD | 36.37% |
| 2014 Q2 | -16.67 Million USD | 10.22% |
| 2014 Q1 | -18.57 Million USD | 3.01% |
| 2014 Q4 | -12.18 Million USD | 27.11% |
| 2013 Q3 | -23.51 Million USD | 28.36% |
| 2013 Q4 | -19.14 Million USD | 18.56% |
| 2013 FY | -19.14 Million USD | -405.88% |
| 2013 Q1 | -33.42 Million USD | -783.07% |
| 2013 Q2 | -32.81 Million USD | 1.81% |
| 2012 Q2 | -11.84 Million USD | 20.08% |
| 2012 Q3 | -8.72 Million USD | 26.34% |
| 2012 Q4 | -3.78 Million USD | 56.61% |
| 2012 FY | -3.78 Million USD | 79.86% |
| 2012 Q1 | -14.81 Million USD | 21.16% |
| 2011 Q3 | -22.01 Million USD | -1189.4% |
| 2011 Q4 | -18.79 Million USD | 14.63% |
| 2011 FY | -18.79 Million USD | -249.86% |
| 2011 Q1 | -1.2 Million USD | 77.56% |
| 2011 Q2 | -1.7 Million USD | -41.62% |
| 2010 FY | -5.37 Million USD | -26.18% |
| 2010 Q4 | -5.37 Million USD | 20.27% |
| 2010 Q3 | -6.73 Million USD | -73.73% |
| 2010 Q2 | -3.87 Million USD | 5.73% |
| 2010 Q1 | -4.11 Million USD | 3.36% |
| 2009 Q3 | -7.38 Million USD | -172.9% |
| 2009 FY | -4.25 Million USD | 52.89% |
| 2009 Q4 | -4.25 Million USD | 42.39% |
| 2009 Q2 | -2.7 Million USD | 38.71% |
| 2009 Q1 | -4.41 Million USD | 51.11% |
| 2008 Q4 | -9.03 Million USD | 34.33% |
| 2008 Q1 | -23.7 Million USD | 23.42% |
| 2008 FY | -9.03 Million USD | 70.81% |
| 2008 Q2 | -19.86 Million USD | 16.22% |
| 2008 Q3 | -13.76 Million USD | 30.71% |
| 2007 Q1 | -17.78 Million USD | 36.51% |
| 2007 FY | -30.95 Million USD | -10.49% |
| 2007 Q3 | -40.02 Million USD | -203.38% |
| 2007 Q4 | -30.95 Million USD | 22.66% |
| 2007 Q2 | -13.19 Million USD | 25.83% |
| 2006 Q3 | -13.61 Million USD | 17.06% |
| 2006 Q4 | -28.01 Million USD | -105.83% |
| 2006 FY | -28.01 Million USD | -78.56% |
| 2006 Q2 | -16.41 Million USD | 28.82% |
| 2006 Q1 | -23.05 Million USD | -46.95% |
| 2005 Q4 | -15.69 Million USD | 37.23% |
| 2005 Q3 | -24.99 Million USD | 12.94% |
| 2005 Q2 | -28.71 Million USD | 9.97% |
| 2005 Q1 | -31.88 Million USD | -78.31% |
| 2005 FY | -15.69 Million USD | 12.26% |
| 2004 FY | -17.88 Million USD | -27.46% |
| 2004 Q4 | -17.88 Million USD | 22.66% |
| 2004 Q3 | -23.12 Million USD | -220.73% |
| 2004 Q1 | -9.58 Million USD | 31.7% |
| 2004 Q2 | -7.2 Million USD | 24.76% |
| 2003 Q2 | -8.27 Million USD | -106.67% |
| 2003 Q1 | -4 Million USD | 49.61% |
| 2003 FY | -14.03 Million USD | -76.61% |
| 2003 Q3 | -22.13 Million USD | -167.54% |
| 2003 Q4 | -14.03 Million USD | 36.61% |
| 2002 Q2 | -15.02 Million USD | -74.28% |
| 2002 Q1 | -8.62 Million USD | 24.57% |
| 2002 Q3 | -10.65 Million USD | 29.1% |
| 2002 FY | -7.94 Million USD | 30.49% |
| 2002 Q4 | -7.94 Million USD | 25.42% |
| 2001 Q2 | -14.86 Million USD | -34.76% |
| 2001 Q4 | -11.42 Million USD | 22.84% |
| 2001 Q3 | -14.81 Million USD | 0.37% |
| 2001 FY | -11.42 Million USD | -254.97% |
| 2001 Q1 | -11.03 Million USD | -242.63% |
| 2000 Q1 | -10.7 Million USD | -3466.67% |
| 2000 FY | -3.21 Million USD | -973.2% |
| 2000 Q2 | -8.3 Million USD | 22.43% |
| 2000 Q3 | -5.49 Million USD | 33.77% |
| 2000 Q4 | -3.21 Million USD | 41.43% |
| 1999 Q1 | -3 Million USD | 16.67% |
| 1999 FY | -300 Thousand USD | 91.67% |
| 1999 Q4 | -300 Thousand USD | 91.89% |
| 1999 Q3 | -3.7 Million USD | -105.56% |
| 1999 Q2 | -1.8 Million USD | 40.0% |
| 1998 Q3 | -4.1 Million USD | 29.31% |
| 1998 FY | -3.6 Million USD | 67.27% |
| 1998 Q1 | -7.9 Million USD | 27.52% |
| 1998 Q2 | -5.8 Million USD | 26.58% |
| 1998 Q4 | -3.6 Million USD | 12.2% |
| 1997 Q1 | -2.2 Million USD | 38.89% |
| 1997 Q2 | -800 Thousand USD | 63.64% |
| 1997 Q4 | -10.9 Million USD | -275.86% |
| 1997 Q3 | -2.9 Million USD | -262.5% |
| 1997 FY | -11 Million USD | -211.09% |
| 1996 FY | -3.53 Million USD | 0.0% |
| 1996 Q4 | -3.6 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | -80.766% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -134.261% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 108.364% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 88.014% |
| Azitra, Inc. | -910.04 Thousand USD | -882.049% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | -110.879% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 862.356% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 272.297% |
| CEL-SCI Corporation | 9.42 Million USD | 194.813% |
| iBio, Inc. | -9.75 Million USD | 8.338% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 72.493% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | -24.982% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -597.663% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 2138.358% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -2191.553% |
| NanoViricides, Inc. | -4.79 Million USD | -86.275% |
| Oragenics, Inc. | -3.17 Million USD | -181.855% |
| BiomX Inc. | -772 Thousand USD | -1057.65% |
| BiomX Inc. | -772 Thousand USD | -1057.65% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 437.63% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 164.494% |